R&D Trends

Soligenix, Intrexon pursue melioidosis therapy through exclusive collaboration

Friday, May 3, 2013 10:48 AM

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, will jointly develop a treatment for melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function.

More... »

Abide Therapeutics, Merck to develop novel therapies for T2D, metabolic diseases

Friday, May 3, 2013 10:19 AM

Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, has entered into a collaboration agreement with Merck, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

More... »

GSK, Impax Pharmaceuticals terminate collaboration on IPX066

Monday, April 29, 2013 02:25 PM

Impax Pharmaceuticals, the brand products division of Impax Laboratories, and GlaxoSmithKline (GSK) are terminating their collaboration for the development and commercialization of IPX066 outside the U.S. and Taiwan.

More... »

Esperion Therapeutics completes $33M financing to advance LDL-C lowering therapy

Friday, April 26, 2013 01:41 PM

Esperion Therapeutics, a clinical stage biopharmaceutical company focused on oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for hypercholesterolemia and other cardiometabolic disorders, has completed a $33 million preferred stock financing led by new investor Longitude Capital.

More... »

CardioDx, Core Diagnostics India ink Corus CAD marketing agreement

Friday, April 26, 2013 12:04 PM

CardioDx, a developer of cardiovascular genomic diagnostics, has signed an agreement granting Core Diagnostics India the exclusive right to market and sell its Corus CAD diagnostic test in India.

More... »

High school junior Natalie Ng wins International BioGENEius Challenge

Friday, April 26, 2013 11:42 AM

Natalie Ng, a junior at Monta Vista High School in Cupertino, Calif., won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Ng’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge's top prize, a $7,500 cash award.

More... »

Michael J. Fox Foundation launches new study arm to investigate risk factors for PD

Friday, April 26, 2013 11:09 AM

The Michael J. Fox Foundation’s Parkinson's Progression Markers Initiative (PPMI), a landmark biomarker clinical study, has completed enrollment of its initial 600-member cohort of Parkinson's patients and controls, and will launch additional study cohorts to leverage the existing PPMI infrastructure and evaluate multiple potential biomarkers for Parkinson's disease (PD). The first of these new cohorts has launched and will investigate risk factors for PD that may enable diagnosis before the onset of motor symptoms.

More... »

BIND Therapeutics, AstraZeneca ink cancer nanomedicine agreement

Monday, April 22, 2013 03:17 PM

BIND Therapeutics, a clinical-stage biopharmaceutical company, and AstraZeneca have entered into a strategic collaboration to develop and commercialize an Accurin, a targeted and programmable cancer nanomedicine from BIND's medicinal nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

More... »

Merck, BMS to conduct phase II trial of MK-5172, daclatasvir for hep C

Monday, April 22, 2013 02:20 PM

Global healthcare company Merck has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of BMS’s investigational NS5A replication complex inhibitor, daclatasvir, and Merck's investigational NS3/4A protease inhibitor, MK-5172, for the treatment of chronic hepatitis C virus (HCV) infection, genotype 1.

More... »

Horizon Discovery, AstraZeneca collaborate on oncology drug discovery

Monday, April 22, 2013 01:54 PM

Horizon Discovery, a provider of research tools to support translational genomics research, and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon's first-in-class kinase target program, HD-001, as a means of developing novel therapies for multiple cancer types.

More... »